The findings also highlight the amalgamation of additional druggable targets for PAK1 and ERK signalling to the currently existing treatment regimens to improve clinical outcomes in CML patients. The gene discussed is PAK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.